-
Mashup Score: 68Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval - 13 day(s) ago
This study aims to determine whether cancer drugs granted accelerated approval from the US Food and Drug Administration ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval.
Source: jamanetwork.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 65Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval - 13 day(s) ago
This study aims to determine whether cancer drugs granted accelerated approval from the US Food and Drug Administration ultimately demonstrate clinical benefit and to evaluate the basis of conversion to regular approval.
Source: jamanetwork.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 80CONGRESO SOCHIRA 2024 | SOCHIRA - 17 day(s) ago
Con mucho agrado anunciamos la “XVIII Congreso Sociedad Chilena de Radioterapia Oncologica” a desarrollarse entre los d í as 11 y 14 de Abril 2024 en Hotel Cumbres de San Pedro de Atacama, Chile. La jornada contar á con la participaci ó n de especialistas en diversas á reas de inter é s a nivel nacional e internacional, orientado principalmente a m é dicos onc ó logos radioterapeutas, tecn ó logos m é dicos, f í sicos m é dicos, y otros profesionales especialistas que trabajan en radioterapia, resultando
Source: www.sochira.clCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 231How public health services pay for radiotherapy in Europe: an ESTRO–HERO analysis of reimbursement - 19 day(s) ago
Reimbursement is a key factor in defining which resources are made available to ensure quality, efficiency, availability, and access to specific health-care interventions. This Policy Review assesses publicly funded radiotherapy reimbursement systems in Europe. We did a survey of the national societies of radiation oncology in Europe, focusing on the general features and global structure of the reimbursement system, the coverage scope, and level for typical indications. The annual expenditure covering radiotherapy in each country was also collected.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet-
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐 @TheLancetOncol - https://t.co/qyAG8X6Rdq “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer https://t.co/yxqNP9FEkA
-
-
Mashup Score: 46CONGRESO SOCHIRA 2024 | SOCHIRA - 19 day(s) ago
Con mucho agrado anunciamos la “XVIII Congreso Sociedad Chilena de Radioterapia Oncologica” a desarrollarse entre los d í as 11 y 14 de Abril 2024 en Hotel Cumbres de San Pedro de Atacama, Chile. La jornada contar á con la participaci ó n de especialistas en diversas á reas de inter é s a nivel nacional e internacional, orientado principalmente a m é dicos onc ó logos radioterapeutas, tecn ó logos m é dicos, f í sicos m é dicos, y otros profesionales especialistas que trabajan en radioterapia, resultando
Source: www.sochira.clCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 18
Our findings suggests that systematic endoscopic mediastinal staging in patients with locally advanced or unresectable NSCLC is more accurate than PET alone in defining extent of mediastinal involvement. Standard guideline-recommended PET-based radiotherapy planning results in suboptimal tumour coverage. Our findings indicate that systematic endoscopic staging should be routinely performed in patients with locally advanced NSCLC being considered for radiotherapy to accurately inform radiation planning and treatment decision making in patients with locally advanced NSCLC.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 15Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases - 2 month(s) ago
Medical operability is prognostic for survival after SABR in primary malignancies. This study investigated the prognostic significance of medical oper…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
We use a similar approach to @ChadTangMD in @PeterMacRadOnc @gu_onc #radonc. We often use SABR alone upfront in oligometastases. We reported a 3- and 5-year freedom from systemic therapy of 40% and 31% with this approach here (n=401, basket histology); https://t.co/7nnDpccrwM https://t.co/SQinSj9n2J https://t.co/AmjE04368P
-
-
Mashup Score: 239Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial - 2 month(s) ago
Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cell cancer who do not undergo surg…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 22
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostShankar Siva@_ShankarSiva1/ Thank you patients, families, trial staff and investigators for participating in @TROGfightcancer 15.03 FASTRACK II! This trial recruited n=70 across 8 sites in and #ASTRO23! #radonc #kcsm #radiotherapy @ANZUPtrials@KidneyCancerAlison Tree and 9 others5:35 PM · Oct 1, 202373.8K…
Source: x.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 28
Surgery is the standard of care for patients with primary renal cell carcinoma. Stereotactic body radiotherapy (SBRT) is a novel alternative for patients who are medically inoperable, technically high risk, or who decline surgery. Evidence for using SBRT in the primary renal cell carcinoma setting is growing, including several rigorously conducted prospective clinical trials. This systematic review was performed to assess the safety and efficacy of SBRT for primary renal cell carcinoma. Review results then formed the basis for the practice guidelines described, on behalf of the International Stereotactic Radiosurgery Society.
Source: www.thelancet.comCategories: General Medicine News, Oncologists2Tweet
📢🔈And then on the other hand... just breaking this month - https://t.co/zganrryaD4 - 19 of 46 cancer drugs (41%) granted accelerated FDA approval from 2013-2017 did not improve overall survival in confirmatory trials; 🧐 #radonc https://t.co/8zBJaAGH4V